Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
about
Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy.Bioengineering strategies for designing targeted cancer therapiesThe effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulationHigh Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis.Targeting liposomes loaded with melphalan prodrug to tumour vasculature via the Sialyl Lewis X selectin ligand.Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric FabMultifunctional, stimuli-sensitive nanoparticulate systems for drug deliverySwitchable probes: pH-triggered and VEGFR2 targeted peptides screening through imprinting microarray.Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing TumorsApplication of liposomes in drug development--focus on gastroenterological targets.Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsCurrent trends in the use of liposomes for tumor targetingTargeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors.Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review).A murine-human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro.Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy.Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.Integrative meta-modeling identifies endocytic vesicles, late endosome and the nucleus as the cellular compartments primarily directing RTK signaling.Orally administered liposomal formulations for colon targeted drug delivery.DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma.Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics.Isolation and characterization of canine tumor endothelial cells.Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review.Targeting of AUF1 to vascular endothelial cells as a novel anti-aging therapy.Inflammation and Cancer: In Medio Stat Nano.Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer.
P2860
Q30421668-A33A1D88-7980-442B-B22A-29844997D5FDQ34194191-84AB4E2B-779B-47C1-B1E2-73C1C7AC01FEQ34270352-27D116B5-1362-4A34-A6BC-556350BACE6EQ34496687-62A681F3-4469-4A7C-9A38-7CF155FC85D1Q35061731-95144730-B2F5-4978-BE01-B99EF54BA384Q35662815-E7DC3DC5-3B02-41AA-A3C7-5F2180B122F7Q35809872-D7F5A762-799E-4E67-9562-460E31344676Q35976673-273D9DAC-8A18-48BE-AB6E-9095C63C1A4EQ36372353-D3473CC7-48B3-4006-A959-96D28666451BQ36758275-B71F1580-01B8-4B10-903A-8630746B7813Q37010760-1B921F60-E280-4183-A7D9-4DD93491241EQ38042256-47A3B4D8-F351-41DA-9D43-8E4D4A477DB3Q38126543-2CAF6CE2-BADF-41BB-B492-AA143CDCF154Q38169752-A907895A-7AFE-4CD4-99AC-471F59A8F434Q38205769-1314CEFC-0DCA-48F2-94C4-3F4B61C12FE3Q38597921-FD675B0C-024F-491E-808B-5FC523EA5F79Q38776676-6ECF4170-E201-425C-BC6F-D01A0ED5E015Q38850036-54030D26-4374-4247-BE54-B4265BA4C8CAQ39361715-2FB143AF-345C-4316-8784-9F782D78316BQ40463360-432B3745-F88C-4E7E-AA3D-15E49BB19B92Q40475538-69913739-2AD5-412E-8EFB-F2A8BDBB92D5Q41898283-8D60F059-3EBF-41D6-B013-ECF2E42DCE90Q41953738-8432FD8A-5FB4-47E8-84AD-796E6BA9E48EQ43214760-67ED6237-333D-4A05-A1D7-93BB5886B3EEQ47190264-F59D2ABE-A1AB-46D9-9023-26D3DD9050C0Q47382076-F1FC009B-B1A6-4913-B137-8956476F2F06Q47877048-42EA8D88-8227-410E-A2D1-7CB5EA01E83FQ54479575-B68CE771-3041-4E46-840B-08F34D881BDC
P2860
Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Targeting tumor-associated end ...... tion and inhibit tumor growth.
@en
Targeting tumor-associated end ...... tion and inhibit tumor growth.
@nl
type
label
Targeting tumor-associated end ...... tion and inhibit tumor growth.
@en
Targeting tumor-associated end ...... tion and inhibit tumor growth.
@nl
prefLabel
Targeting tumor-associated end ...... tion and inhibit tumor growth.
@en
Targeting tumor-associated end ...... tion and inhibit tumor growth.
@nl
P2093
P1476
Targeting tumor-associated end ...... tion and inhibit tumor growth.
@en
P2093
Annette Orleth
Christoph Mamot
Christoph Rochlitz
Gerhard Christofori
Imke Albrecht
Reto Ritschard
Richard Herrmann
P304
P356
10.1158/1078-0432.CCR-11-1102
P407
P577
2011-11-07T00:00:00Z